Advertisement
Free access | 10.1172/JCI109013
The Department of Medicine and the Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118
The Department of Pharmacology and the Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118
Cardiology Department of the Medical Service, Boston, Massachusetts 02118
Hypertension Department of the Medical Service, Boston, Massachusetts 02118
Thorndike Memorial Laboratories, Boston City Hospital, Boston, Massachusetts 02118
Department of Medicine, University Hospital, Boston, Massachusetts 02118
Department of Clinical Research, University Hospital, Boston, Massachusetts 02118
Find articles by Liang, C. in: JCI | PubMed | Google Scholar
The Department of Medicine and the Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118
The Department of Pharmacology and the Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118
Cardiology Department of the Medical Service, Boston, Massachusetts 02118
Hypertension Department of the Medical Service, Boston, Massachusetts 02118
Thorndike Memorial Laboratories, Boston City Hospital, Boston, Massachusetts 02118
Department of Medicine, University Hospital, Boston, Massachusetts 02118
Department of Clinical Research, University Hospital, Boston, Massachusetts 02118
Find articles by Gavras, H. in: JCI | PubMed | Google Scholar
The Department of Medicine and the Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118
The Department of Pharmacology and the Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118
Cardiology Department of the Medical Service, Boston, Massachusetts 02118
Hypertension Department of the Medical Service, Boston, Massachusetts 02118
Thorndike Memorial Laboratories, Boston City Hospital, Boston, Massachusetts 02118
Department of Medicine, University Hospital, Boston, Massachusetts 02118
Department of Clinical Research, University Hospital, Boston, Massachusetts 02118
Find articles by Hood, W. in: JCI | PubMed | Google Scholar
Published April 1, 1978 - More info
The role of the renin-angiotensin system in the regulation of the systemic and coronary circulations during sodium depletion was studied in conscious normotensive dogs by i.v. administration of teprotide (0.5 mg/kg), an angiotensin-converting enzyme inhibitor, and saralasin (0.05-5 μg/kg per min), an angiotensin-receptor antagonist. Sodium depletion was produced by administering a low sodium diet and furosemide for 5 days. Administration of both teprotide and saralasin lowered systemic arterial blood pressure and total peripheral vascular resistance. Simultaneously, cardiac output increased, but left ventricular end-diastolic pressure, dP/dt, and dP/dt/P did not change significantly. Furthermore, both agents reduced diastolic coronary vascular resistance and increased coronary blood flow, but did not affect myocardial oxygen consumption, left ventricular work, or myocardial efficiency. These systemic and coronary vasodilator effects of teprotide and saralasin, however, were not observed in normal dogs on a regular sodium diet; in this group, the only effect noted was a slight increase in arterial pressure during saralasin infusion. Arterial plasma concentration of norepinephrine did not differ between normal and sodiumdepleted dogs, nor did it change significantly after teprotide administration. These results suggest that, during salt depletion, angiotensin II exerts an active vasoconstrictor action on the systemic and coronary vessels, but has no significant effects on myocardial contractility or energetics. It also appears likely that the increase in cardiac output observed in sodiumdepleted dogs after angiotensin inhibition was caused, at least in part, by the decrease in systemic arterial pressure.